ArticleFrontiers in cardiovascular medicine2025
Risk factors for acute kidney injury and its impact on 3-year mortality after thoracic endovascular repair for type B aortic dissection.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Acute kidney injury (AKI) following thoracic endovascular aortic repair (TEVAR) significantly impacts outcomes. This study aimed to identify independent predictors of AKI after TEVAR for acute Stanford type B aortic dissection (ATBAD) and evaluate its impact on long-term mortality. Methods: This retrospective analysis included 745 consecutive patients who underwent TEVAR for ATBAD at the General Hospital of Northern Theater Command between February 2004 and November 2022. Acute kidney injury was diagnosed based on a serum creatinine increase of ≥26.5 μmol/L within 48 h, a ≥1.5-fold increase from baseline within 7 days, or urine output <0.5 mL/kg/h for 6 h. Univariate and multivariate logistic regressions identified risk factors for AKI and all-cause mortality. Results: AKI occurred in 75 patients (10.1%). The patients who developed AKI had a higher baseline serum creatinine level (85.97 vs. 78.30 μmol/L; Conclusions: AKI remains highly prevalent in patients undergoing TEVAR for ATBAD. Bilateral renal artery involvement, elevated baseline creatinine, and contrast volume >290 mL independently predicted AKI. Development of AKI was associated with a threefold increase in long-term mortality, emphasizing the importance of risk stratification and nephroprotective strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.